A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
Study Details
Study Description
Brief Summary
This study was designed to explore the safety and efficacy of Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy or Fluzoparib monotherapy in patients with platinum-resistant recurrent ovarian cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
This purpose of this study is to explore efficacy of Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy or Fluzoparib monotherapy in patients with platinum-resistant recurrent ovarian cancer.Besides the efficacy,we focus on the safety and quality of life in the new treatments.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Bevacizumab combined with Fluzoparib Bevacizumab combined with Fluzoparib will be administered in patients with platinum-resistant recurrent ovarian cancer. |
Drug: Bevacizumab
Bevacizumab will be administered at 15mg/kg IV, every 3 weeks
Other Names:
Drug: chemotherapy
The non-platinum chemotherapy regimen will be determined by the investigator.
Other Names:
|
| Experimental: Bevacizumab combined with chemotherapy Bevacizumab combined with non-platinum chemotherapy will be administered in patients with platinum-resistant recurrent ovarian cancer. |
Drug: Bevacizumab
Bevacizumab will be administered at 15mg/kg IV, every 3 weeks
Other Names:
Drug: chemotherapy
The non-platinum chemotherapy regimen will be determined by the investigator.
Other Names:
|
| Experimental: Fluzoparib Fluzoparib monotherapy will be administered in patients with platinum-resistant recurrent ovarian cancer. |
Drug: Fluzoparib
Fluzoparib will be administered orally continuously at 150mg bid until disease progression and toxicity becomes intolerable
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Progression-Free-Survival [2 years]
The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse
Secondary Outcome Measures
- Objective remission rate [2 years]
It refers to the proportion of patients (mainly solid tumors) whose tumor has shrunk to a certain extent and remained there for a certain period of time, including Complete Response (CR) and Partial Response (PR).
- Overall Survival [2 years]
Time from randomization to death from any cause (for subjects who have been lost to follow-up prior to death, the time of death is usually calculated as the time of last follow-up)
- Adverse event Adverse event [2 years]
It refers to all adverse medical events that occur after a subject receives an investigational drug, which may be manifested as symptoms, signs, diseases, or abnormalities in laboratory tests, but may not necessarily be causally related to the investigational drug
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥18 years, female;
-
Recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer proven to be platinum-resistant by histology or cytology;
-
ECOG score was 0-1;
-
Expected survival time > 12 weeks;
-
Normal or abnormal bone marrow, kidney, and liver function of the patient has no clinical significance, and the specific situation will be comprehensively determined by the investigator;
-
Patients not previously treated with PARPi or targeted drugs;
-
The patient has taken effective contraceptive measures within 14 days prior to screening and is willing to sign the notification until the last medication No pregnancy plan and voluntary use of effective contraceptive measures within the next 6 months;
-
The subject or his/her legal guardian can communicate well with the investigator, understand and comply with the requirements of this study, and understand and sign the informed consent.
Exclusion Criteria:
-
Known allergy to fluzopalil or study drug components;
-
Patients with any factors affecting oral administration (such as previous gastric or small bowel resection, or current atrophic gastritis, chronic intestinal disease, gastrointestinal bleeding, dysphagia, gastrointestinal obstruction, or diarrhea greater than grade 1, including those who have recovered but have not recovered);
-
Patients who underwent major surgery or gastrointestinal surgery affecting drug absorption, open biopsy, severe traumatic injury, wound unhealed or did not recover from major surgery within 1 month before the trial;
-
Before the first administration, patients have used strong CYP3A inhibitors (such as itraconazole, telithromycin, clarithromycin, ritonavir, etc.) or medium CYP3A inhibitors (such as ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil, etc.); Patients who had used strong CYP3A inducers (e.g., phenobarbide, enzyluamide, phenytoin, rifampicin, rifambutin, rifapentine, carbamazepine, nevirapine and St. John's herb) or medium CYP3A inducers (e.g., Bosentan, efavirenz, modafinil, etc.) and did not reach 3 elimination half-lives;
-
Pregnant or lactating women or subjects who cannot use contraception as required;
-
Those who have special requirements on diet and cannot accept uniform diet;
-
As judged by the researcher, there are other circumstances that are not suitable for the researcher.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The Second Affiliated Hospital of Shandong First Medical University | Tai'an | Shandong | China | 271000 |
Sponsors and Collaborators
- The Second Affiliated Hospital of Shandong First Medical University
Investigators
- Principal Investigator: Haiyan Liu, The Second Affiliated Hospital of Shandong First Medical University
Study Documents (Full-Text)
None provided.More Information
Publications
- Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Loman N, Robertson JD, Mann H, Kaufman B. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016 Feb;140(2):199-203. doi: 10.1016/j.ygyno.2015.12.020. Epub 2015 Dec 23.
- Mellinghoff IK, Chang SM, Jaeckle KA, van den Bent M. Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. Hematol Oncol Clin North Am. 2022 Feb;36(1):95-111. doi: 10.1016/j.hoc.2021.08.008. Epub 2021 Oct 25. Review.
- Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Erratum in: Lancet Oncol. 2019 May;20(5):e242.
- MT-004